Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Zambelli

Showing results (61-70 of 162) with videos related to

Pageof 17
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 3, 2015
Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survivalMarta Rossi, Greta Carioli, Martina Bonifazi, et al.
Biomedicines|March 28, 2024
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast CancerGiuseppe Saltalamacchia, Rosalba Torrisi, Rita De Sanctis, et al.
Cancers|December 23, 2022
Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line ChemotherapyCorrado Tinterri, Andrea Sagona, Erika Barbieri, et al.
NPJ Breast Cancer|January 25, 2023
The central role of pathology labs in breast cancer precision oncology: a call for actionGiancarlo Pruneri, Daniele Lorenzini, Mauro G Mastropasqua, et al.
Cancer Treatment Reviews|January 17, 2013
Targeting triple negative breast cancer: is p53 the answer?Natalie Turner, Erica Moretti, Olimpia Siclari, et al.
Cancer|May 17, 2002
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignanciesPaolo Pedrazzoli, Gian Antonio Da Prada, Giovanna Giorgiani, et al.
Molecular & Cellular Proteomics : MCP|November 4, 2015
Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast CancerElisa Maurizio, Jacek R Wiśniewski, Yari Ciani, et al.
La Radiologia Medica|December 1, 2025
[<sup>18</sup>F]FDG PET/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies?Riccardo Gerosa, Fabrizia Gelardi, Paola Tiberio, et al.
The Oncologist|May 14, 2025
Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patientsJacopo Canzian, Damiano Gentile, Rita De Sanctis, et al.
The Oncologist|May 20, 2024
Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizerRita De Sanctis, Paola Tiberio, Flavia Jacobs, et al.
Pageof 17

Showing results (61-70 of 162) with videos related to

Sort By:
Pageof 17
European Journal of Cancer (Oxford, England : 1990)|December 3, 2015
Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survivalMarta Rossi, Greta Carioli, Martina Bonifazi, et al.
Biomedicines|March 28, 2024
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast CancerGiuseppe Saltalamacchia, Rosalba Torrisi, Rita De Sanctis, et al.
Cancers|December 23, 2022
Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line ChemotherapyCorrado Tinterri, Andrea Sagona, Erika Barbieri, et al.
NPJ Breast Cancer|January 25, 2023
The central role of pathology labs in breast cancer precision oncology: a call for actionGiancarlo Pruneri, Daniele Lorenzini, Mauro G Mastropasqua, et al.
Cancer Treatment Reviews|January 17, 2013
Targeting triple negative breast cancer: is p53 the answer?Natalie Turner, Erica Moretti, Olimpia Siclari, et al.
Cancer|May 17, 2002
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignanciesPaolo Pedrazzoli, Gian Antonio Da Prada, Giovanna Giorgiani, et al.
Molecular & Cellular Proteomics : MCP|November 4, 2015
Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast CancerElisa Maurizio, Jacek R Wiśniewski, Yari Ciani, et al.
La Radiologia Medica|December 1, 2025
[<sup>18</sup>F]FDG PET/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies?Riccardo Gerosa, Fabrizia Gelardi, Paola Tiberio, et al.
The Oncologist|May 14, 2025
Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patientsJacopo Canzian, Damiano Gentile, Rita De Sanctis, et al.
The Oncologist|May 20, 2024
Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizerRita De Sanctis, Paola Tiberio, Flavia Jacobs, et al.
Pageof 17